Aankondiging • May 03
Ellomay Capital Ltd. announced delayed 20-F filing On 05/01/2026, Ellomay Capital Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Reported Earnings • Apr 06
Full year 2025 earnings released: €0.14 loss per share (vs €0.52 loss in FY 2024) Full year 2025 results: €0.14 loss per share (improved from €0.52 loss in FY 2024). Revenue: €42.8m (up 5.8% from FY 2024). Net loss: €1.77m (loss narrowed 73% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance. Aankondiging • Mar 06
Ellomay Capital Ltd. Announces Board and Committee Changes Ellomay Capital Ltd. on March 4, 2026 announced that its principal shareholders, S. Nechama Investments (2008) Ltd., Kanir Joint Investments (2005) LP and Ms. Anat Raphael, who together currently hold approximately 45.9% of the Company’s outstanding share capital, informed it that they have completed the sale of all of the Company’s ordinary shares held by them to O.Y. Nofar Energy Ltd. In connection with the sale of the shares, two members of the Company’s Board of Directors, Ms. Anita Leviant and Mr. Ehud Gil, resigned from the Board effective March 4, 2026 and the Chairman of the Board of Directors, Mr. Ben Sheizaf, informed the Company that he will resign from the Board of Directors effective 30 days from the consummation of the sale of the shares. The Board of Directors unanimously appointed two new independent non-executive directors to fill the vacancies created, Ms. Odelya Ohayon and Mr. Gilad Mamlok. Mr. Mamlok was appointed as a member of the Audit Committee and the Compensation Committee, replacing Ms. Leviant. Odelya Ohayon is a strategic leader and business development expert with over 15 years of executive experience. She currently provides high-level strategic advisory to CEOs and Boards, focusing on business strategy and innovation. Previously, she served as VP of Marketing at Samsung Electronics Israel, where she was a member of the Executive Management Team and managed an annual turnover of NIS 1.5 billion. Her prior leadership roles include VP of Marketing and Business Development at Solgar & Supherb and Marketing Manager at Partner Communications, where she managed portfolios exceeding NIS 2 billion. Ms. Ohayon is a lecturer in marketing and entrepreneurship at the College of Management and Ariel University. She holds a B.A. in Business Administration from Ben-Gurion University and an M.B.A. from the Academic Studies Center. Gilad Mamlok serves as the Chief Financial Officer of Protalix BioTherapeutics Inc. since August 2025. Mr. Mamlok is a seasoned financial executive with three decades of experience in healthcare and technology companies. He has an extensive background in capital markets transactions, mergers and acquisitions, business development and investor relations as well as in corporate governance matters. Prior to his role in Protalix, he served as the Chief Financial Officer of TytoCare Ltd. Prior to his role at TytoCare, Mr. Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. In this role, he was responsible for an initial public offering and other capital markets transactions, as well as in-licensing and out-licensing transactions. Prior to his role at Sol-Gel, he served in other medical device companies, including Given Imaging which was acquired by Covidien plc in 2014. Mr. Mamlok holds a BA in Economics, magna cum laude, and a Master’s degree in Business/Managerial Economics, both from the Tel Aviv University. Aankondiging • Mar 05
O.Y. Nofar Energy Ltd (TASE:NOFR) completed the acquisition of 45.90% stake in Ellomay Capital Ltd. (NYSEAM:ELLO) from Kanir Joint Investments (2005) Limited Partnership, Anat Raphael and S. Nechama Investments 2008, Ltd. O.Y. Nofar Energy Ltd (TASE:NOFR) executed an agreement to acquire 45.90% stake in Ellomay Capital Ltd. (NYSEAM:ELLO) from Kanir Joint Investments (2005) Limited Partnership, Anat Raphael and S. Nechama Investments 2008, Ltd. on December 16, 2025. As part of the acquisition, Ran Fridrich will continue as Chief Executive Officer of the Ellomay Capital. Ellomay will continue to operate in the ordinary course of business, while retaining its dedicated employees and management backbone, and will work to expand its activities in the future. The Trustee is required to convene such a meeting at the request of a holder that holds at least 5% of the outstanding par value of a series of debentures. Accordingly, the Trustee published a notice convening a joint meeting of holders of the Company’s Series E and Series F debentures to be held on Tuesday, December 30, 2025, for purposes of a discussion (which will not include a vote) regarding the expected sale of control stake. The Sellers will be selling their shares based on a Company valuation of ILS 1 billion (approximately $310.4 million), subject to customary adjustments.
The transaction is subject to approval by Israeli Electricity Authority and the Israeli Competition Commissioner. As of February 12, 2026, The conditions to closing to the acquisition by Nofar of control of the Company from three existing shareholders have been fulfilled. Nofar notes in its report that the consummation of this transaction is expected in the coming days. As the Company is not a party to the transaction, it cannot estimate the timing for the consummation of the transaction. As of February 18, 2026, Completion is expected in the coming days.
O.Y. Nofar Energy Ltd (TASE:NOFR) completed the acquisition of 45.90% stake in Ellomay Capital Ltd. (NYSEAM:ELLO) from Kanir Joint Investments (2005) Limited Partnership, Anat Raphael and S. Nechama Investments 2008, Ltd. on March 4, 2026. In connection with the sale of the shares, two members of Ellomay Board of Directors, Anita Leviant and Ehud Gil, resigned from the Board effective immediately and the Chairman of the Board of Directors, Ben Sheizaf, informed the Company that he will resign from the Board of Directors effective 30 days from the consummation of the sale of the shares. The Board of Directors unanimously appointed two new independent non-executive directors to fill the vacancies created Odelya Ohayon and Gilad Mamlok. Mamlok was appointed as a member of the Audit Committee and the Compensation Committee, replacing Leviant. Reported Earnings • Dec 31
Third quarter 2025 earnings released: EPS: €0.79 (vs €0.47 in 3Q 2024) Third quarter 2025 results: EPS: €0.79 (up from €0.47 in 3Q 2024). Revenue: €12.7m (up 3.2% from 3Q 2024). Net income: €10.1m (up 66% from 3Q 2024). Profit margin: 80% (up from 50% in 3Q 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. New Risk • Oct 05
New major risk - Revenue and earnings growth Earnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.3% operating cash flow to total debt). Earnings have declined by 2.6% per year over the past 5 years. Reported Earnings • Oct 01
Second quarter 2025 earnings released: €0.60 loss per share (vs €0.13 profit in 2Q 2024) Second quarter 2025 results: €0.60 loss per share (down from €0.13 profit in 2Q 2024). Revenue: €11.3m (flat on 2Q 2024). Net loss: €7.68m (down €9.47m from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Aankondiging • Sep 15
Ellomay Capital Ltd., Annual General Meeting, Oct 23, 2025 Ellomay Capital Ltd., Annual General Meeting, Oct 23, 2025. Location: 18 rothschild boulevard, 1st floor, 6688121., tel aviv Israel Aankondiging • Jul 15
Ellomay Capital Ltd. announced that it expects to receive ILS 50.004 million in funding Ellomay Capital Ltd announces a private placement to issue 926,000 ordinary shares at a price of NIS 54 per share for gross proceeds of NIS 50,004,000 on July 14, 2025. The closing of the Private Placement is subject to the receipt of regulatory approvals, which are expected to be obtained during July 2025. Reported Earnings • Jul 02
First quarter 2025 earnings released: EPS: €0.62 (vs €0.26 loss in 1Q 2024) First quarter 2025 results: EPS: €0.62 (up from €0.26 loss in 1Q 2024). Revenue: €8.86m (up 7.5% from 1Q 2024). Net income: €7.99m (up €11.3m from 1Q 2024). Profit margin: 90% (up from net loss in 1Q 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 01
Full year 2024 earnings released: €0.55 loss per share (vs €0.31 profit in FY 2023) Full year 2024 results: €0.55 loss per share (down from €0.31 profit in FY 2023). Revenue: €40.5m (down 17% from FY 2023). Net loss: €7.12m (down 278% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Reported Earnings • Jan 03
Third quarter 2024 earnings released: EPS: €0.47 (vs €0.41 in 3Q 2023) Third quarter 2024 results: EPS: €0.47 (up from €0.41 in 3Q 2023). Revenue: €12.3m (down 21% from 3Q 2023). Net income: €6.10m (up 17% from 3Q 2023). Profit margin: 50% (up from 34% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Aankondiging • Nov 26
Ellomay Capital Ltd. Announces Board Changes Ellomay Capital Ltd. announced that Shlomo Nehama, after serving as chairman of the board for 16 years, has decided to resign from the Company’s Board of Directors. Mr. Nehama served on the Board of Directors and as the Company’s Chairman of the Board since March 2008 and is a controlling shareholder of the Company. In connection with Mr. Nehama’s resignation, the Company’s Board of Directors unanimously appointed Mr. Ben Sheizaf as a member of the Board of Directors and as Chairman of the Board. Mr. Sheizaf will serve as a director until the Company’s 2025 annual general meeting, at which he can be nominated for reappointment to the Company’s Board of Directors. Mr. Sheizaf, 67, is the founder and CEO of B.P.O. Ltd., a consulting firm since 2019, and has held many senior positions in the Israeli finance and insurance sectors. Mr. Sheizaf currently serves as a member of the board and chairman of the risk management committee of Isracard Ltd. (TASE: ISCD) and as chairman of the board of Detelix Software Technologies Ltd. Between 2008-2019 he held several positions in Phoenix Financial Ltd. (TASE: PHOE), including Deputy CEO and Head of the Long-Term Savings Division, CEO of The Phoenix Pension and Provident Fund Ltd. and a board member of other companies in the group, chairman of Excellence Provident Fund Ltd. and a member of the board of Excellence Investments Ltd. (between 2018-2019), and chairman of Shekel Insurance Agency (2008) Ltd. (between 2012-2015). Mr. Sheizaf holds a B.A. in Accounting and Economics from Tel Aviv University and completed a supplemental year of accounting studies. Reported Earnings • Oct 01
Second quarter 2024 earnings released: EPS: €0.033 (vs €0.11 in 2Q 2023) Second quarter 2024 results: EPS: €0.033. Revenue: €11.2m (down 17% from 2Q 2023). Net income: €1.79m (up 28% from 2Q 2023). Profit margin: 16% (up from 10% in 2Q 2023). The increase in margin was driven by lower expenses. Aankondiging • Aug 20
Ellomay Capital Ltd. announced that it expects to receive ILS 50 million in funding Ellomay Capital Ltd. announced that it has accepted undertakings from Israeli classified investors to participate in a private placement of ILS 2,029,136 par value of its unsecured non-convertible Series F Debentures at a price of ILS 0.961 per 1 principal amount of the Additional Series F Debentures, for an aggregate gross consideration of ILS 50,000,000 on August 19, 2024. Following completion of the private placement, the aggregate outstanding par value of the Company’s Series F Debentures will be NIS 262,029,136. The issuance of the Additional Series F Debentures is subject to the receipt of an approval from the Tel Aviv Stock Exchange for the listing of the Additional Series F Debentures for trading on the Tel Aviv Stock Exchange. Resales of the Additional Series F Debentures will be restricted under applicable securities laws. Reported Earnings • Jul 02
First quarter 2024 earnings released: €0.26 loss per share (vs €0.27 profit in 1Q 2023) First quarter 2024 results: €0.26 loss per share (down from €0.27 profit in 1Q 2023). Revenue: €8.24m (down 32% from 1Q 2023). Net loss: €3.30m (down 191% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Aankondiging • Jun 15
Ellomay Capital Ltd., Annual General Meeting, Jul 25, 2024 Ellomay Capital Ltd., Annual General Meeting, Jul 25, 2024. Location: 18 rothschild boulevard, 1st floor, tel aviv 6688121, Israel Board Change • May 10
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent External Director Dorit Ben Simon was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 02
Full year 2023 earnings released: EPS: €0.31 (vs €0.028 loss in FY 2022) Full year 2023 results: EPS: €0.31 (up from €0.028 loss in FY 2022). Revenue: €48.8m (down 8.5% from FY 2022). Net income: €4.01m (up €4.36m from FY 2022). Profit margin: 8.2% (up from net loss in FY 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 26
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to US$18.85, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 23x in the Renewable Energy industry in the US. Total loss to shareholders of 39% over the past three years. Board Change • Jan 11
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent External Director Dorit Ben Simon was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Aankondiging • Dec 12
Ellomay Capital Ltd. Announces Board Changes Ellomay Capital approved to elect Dorit Ben Simon as an external director for a first three-year term at its Annual General Meeting held on December 11, 2023. Aankondiging • Nov 03
Ellomay Capital Ltd., Annual General Meeting, Dec 11, 2023 Ellomay Capital Ltd., Annual General Meeting, Dec 11, 2023, at 15:00 Israel Standard Time. Location: 18 Rothschild Boulevard, 1st Floor Tel Aviv Israel Agenda: To consider Re-election of Shlomo Nehama, Ran Fridrich, Anita Leviant and Ehud Gil as directors; to consider Re-election of Daniel Vaknin as an external director for a second three-year term; to consider election of Dorit Ben Simon as an external director for a first three-year term; to consider approval of the terms of service the external directors and update to the terms of service of non-executive directors; to consider approval of grant of options to the external directors; to consider approval of terms of service of Ehud Gil, a member of the Board of Directors; and to consider other matters. Aankondiging • Oct 12
Ellomay Capital Ltd. Announces Construction Works in the Site of the Pumped Storage Project in the Manara Cliff, Israel Were Halted Ellomay Capital Ltd. announced that due to the recent hostilities and tensions in northern Israel in recent days following the commencement of the War in Israel, construction works in the site of the Company’s pumped storage project in the Manara Cliff, Israel were halted. Planning works continue without interruption. Valuation Update With 7 Day Price Move • Oct 09
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to US$12.62, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 28x in the Renewable Energy industry in the US. Total loss to shareholders of 63% over the past three years. Reported Earnings • Sep 29
Second quarter 2023 earnings released: EPS: €0.11 (vs €0.13 in 2Q 2022) Second quarter 2023 results: EPS: €0.11 (down from €0.13 in 2Q 2022). Revenue: €13.4m (down 23% from 2Q 2022). Net income: €1.40m (down 19% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year. Reported Earnings • Jul 01
First quarter 2023 earnings released: EPS: €0.27 (vs €0.23 loss in 1Q 2022) First quarter 2023 results: EPS: €0.27 (up from €0.23 loss in 1Q 2022). Revenue: €12.0m (up 2.3% from 1Q 2022). Net income: €3.61m (up €6.55m from 1Q 2022). Profit margin: 30% (up from net loss in 1Q 2022). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 10
Full year 2022 earnings released: €0.028 loss per share (vs €1.18 loss in FY 2021) Full year 2022 results: €0.028 loss per share (improved from €1.18 loss in FY 2021). Revenue: €53.4m (up 17% from FY 2021). Net loss: €357.0k (loss narrowed 98% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Reported Earnings • Dec 30
Third quarter 2022 earnings released: €0.20 loss per share (vs €0.17 loss in 3Q 2021) Third quarter 2022 results: €0.20 loss per share (further deteriorated from €0.17 loss in 3Q 2021). Revenue: €15.5m (up 17% from 3Q 2021). Net loss: €2.56m (loss widened 19% from 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Reported Earnings • Sep 23
Second quarter 2022 earnings released: EPS: €0.13 (vs €0.28 loss in 2Q 2021) Second quarter 2022 results: EPS: €0.13 (up from €0.28 loss in 2Q 2021). Revenue: €17.4m (up 42% from 2Q 2021). Net income: €1.71m (up €5.22m from 2Q 2021). Profit margin: 9.8% (up from net loss in 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 30
First quarter 2022 earnings released: €0.23 loss per share (vs €0.16 loss in 1Q 2021) First quarter 2022 results: €0.23 loss per share (down from €0.16 loss in 1Q 2021). Revenue: €11.8m (up 63% from 1Q 2021). Net loss: €2.93m (loss widened 42% from 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 02
Full year 2021 earnings released: €1.20 loss per share (vs €0.38 loss in FY 2020) Full year 2021 results: €1.20 loss per share (down from €0.38 loss in FY 2020). Revenue: €44.8m (up 364% from FY 2020). Net loss: €15.4m (loss widened 233% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance. Reported Earnings • Dec 29
Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2021 results: €0.17 loss per share (down from €0.07 loss in 3Q 2020). Revenue: €13.3m (up 406% from 3Q 2020). Net loss: €2.15m (loss widened 128% from 3Q 2020). Revenue exceeded analyst estimates by 8.4%. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 54% per year, which means it is well ahead of earnings. Reported Earnings • Oct 01
Second quarter 2021 earnings released: €0.28 loss per share (vs €0.17 loss in 2Q 2020) The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: €12.3m (up 440% from 2Q 2020). Net loss: €3.51m (loss widened 71% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 02
Full year 2020 earnings released: €0.38 loss per share (vs €1.09 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: €9.65m (down 49% from FY 2019). Net loss: €4.63m (down 138% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 24
New 90-day low: US$29.30 The company is down 12% from its price of US$33.40 on 24 November 2020. The American market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Renewable Energy industry, which is up 18% over the same period. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €29.30, the stock is trading at a trailing P/E ratio of 30x, down from the previous P/E ratio of 35.9x. This compares to an average P/E of 63x in the Renewable Energy industry in the US. Total returns to shareholders over the past three years are 217%. Is New 90 Day High Low • Jan 27
New 90-day low: US$31.41 The company is down 14% from its price of US$36.62 on 29 October 2020. The American market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Renewable Energy industry, which is up 33% over the same period. Reported Earnings • Dec 30
Third quarter 2020 earnings released: €0.07 loss per share The company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: €2.63m (down 49% from 3Q 2019). Net loss: €940.0k (down 183% from profit in 3Q 2019). Over the last 3 years on average, earnings per share has increased by 116% per year but the company’s share price has only increased by 55% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Oct 28
New 90-day high: US$37.58 The company is up 42% from its price of US$26.45 on 29 July 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Renewable Energy industry, which is up 16% over the same period. Valuation Update With 7 Day Price Move • Oct 12
Market bids up stock over the past week After last week's 16% share price gain to €33.75, the stock is trading at a trailing P/E ratio of 29.6x, up from the previous P/E ratio of 25.5x. This compares to an average P/E of 48x in the Renewable Energy industry in the US. Total returns to shareholders over the past three years are 299%. Is New 90 Day High Low • Oct 09
New 90-day high: US$31.56 The company is up 35% from its price of US$23.44 on 10 July 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Renewable Energy industry, which is up 22% over the same period. Is New 90 Day High Low • Sep 23
New 90-day high: US$30.19 The company is up 39% from its price of US$21.74 on 24 June 2020. The American market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Renewable Energy industry, which is up 12% over the same period.